Head-to-head · WeighScore
Cost Plus Drugs vs Gala Health
The verdict
Gala Health takes it — 82.9/100 to 58.5/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Cost Plus Drugs | Gala Health |
|---|---|---|
| WeighScore | 58.5/100 | 82.9/100 |
| Grade | C | B− |
| Scorecard rank | #370 | #17 |
| Semaglutide | $279/mo (brand Ozempic) | Not disclosed |
| Tirzepatide | Not disclosed | $179/mo (yearly subscription) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #370 · C
Strengths
- Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
- Around $279/mo for branded Ozempic — well below typical retail list prices
- Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
- Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
- Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing
Where it loses points
- Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
- Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
- Wegovy availability has been spotty — check current stock before assuming it ships
- No compounded semaglutide or tirzepatide — brand only
- No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.